Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

58 trials with published results (31%)

Research Maturity

112 completed trials (59% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

8.9%

17 terminated out of 190 trials

Success Rate

86.8%

+0.3% vs benchmark

Late-Stage Pipeline

33%

63 trials in Phase 3/4

Results Transparency

52%

58 of 112 completed with results

Key Signals

58 with results87% success17 terminated

Data Visualizations

Phase Distribution

174Total
Not Applicable (57)
Early P 1 (5)
P 1 (12)
P 2 (37)
P 3 (36)
P 4 (27)

Trial Status

Completed112
Recruiting26
Terminated17
Unknown16
Withdrawn8
Active Not Recruiting6

Trial Success Rate

86.8%

Benchmark: 86.5%

Based on 112 completed trials

Clinical Trials (190)

Showing 20 of 20 trials
NCT06372964Phase 3RecruitingPrimary

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

NCT07740694Recruiting

EEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT

NCT02719392Phase 4Withdrawn

A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression

NCT03336918Completed

Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder

NCT03573349Early Phase 1Active Not Recruiting

Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:

NCT03748446Early Phase 1Active Not Recruiting

Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder

NCT07266545Phase 4Recruiting

RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)

NCT07172516Phase 3Recruiting

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

NCT07217860Phase 3Enrolling By InvitationPrimary

An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

NCT07021508Not ApplicableRecruitingPrimary

Efficacy and Safety Assessment of Temporal Interference Stimulation to Improve Bipolar Depression

NCT06516991Not ApplicableCompletedPrimary

Task-State-Based Temporal Interference Stimulation (TI) to Improve Depression in Patients With Bipolar Disorder

NCT06560957Not ApplicableRecruitingPrimary

SYNCED - SYNChronized Eating in Bipolar Depression Study

NCT05228964Not ApplicableCompleted

Focused Ultrasound Amygdala Neuromodulation

NCT05054699Phase 2Active Not Recruiting

Electro-Magnetic Convulsive Therapies for Depression: a Non-inferiority Study

NCT05060549Phase 4WithdrawnPrimary

Dopamine D3 Receptor Occupancy in Bipolar Depression

NCT03484494Not ApplicableActive Not Recruiting

Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression

NCT06370988Not ApplicableRecruitingPrimary

Theta-Burst Stimulation for Bipolar Depression

NCT07472920Not ApplicableNot Yet Recruiting

Empagliflozin Adjunctive Therapy in Bipolar Depression

NCT05004896Phase 2Completed

Ketamine for Treatment-Resistant Bipolar Disorder

NCT05357313Not ApplicableActive Not RecruitingPrimary

Adjunctive Bright Light Therapy in Patients With Bipolar Depression and Eveningness

Scroll to load more

Research Network

Activity Timeline